How to step down asthma preventer treatment in patients with well-controlled asthma - more is not always better.

IF 3.4 Q2 PHARMACOLOGY & PHARMACY Australian Prescriber Pub Date : 2022-08-01 DOI:10.18773/austprescr.2022.033
Helen K Reddel, Gloria J Foxley, Sharon R Davis
{"title":"How to step down asthma preventer treatment in patients with well-controlled asthma - more is not always better.","authors":"Helen K Reddel,&nbsp;Gloria J Foxley,&nbsp;Sharon R Davis","doi":"10.18773/austprescr.2022.033","DOIUrl":null,"url":null,"abstract":"<p><p>Most of the benefit of asthma preventer inhalers is seen with low doses. However, many Australian patients are prescribed doses of inhaled corticosteroids that are higher than necessary to control their asthma. Prescribing unnecessarily high preventer doses increases the patient's risk of adverse effects. They may also increase the patient's out-of-pocket costs. Asthma guidelines recommend considering a step-down in preventer treatment after asthma has been well controlled for two to three months in adults and for six months in children. The step-down process should be individualised for each patient. Preventive therapy should not be stopped completely.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/04/f8/austprescr-45-125.PMC9427634.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australian Prescriber","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18773/austprescr.2022.033","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 1

Abstract

Most of the benefit of asthma preventer inhalers is seen with low doses. However, many Australian patients are prescribed doses of inhaled corticosteroids that are higher than necessary to control their asthma. Prescribing unnecessarily high preventer doses increases the patient's risk of adverse effects. They may also increase the patient's out-of-pocket costs. Asthma guidelines recommend considering a step-down in preventer treatment after asthma has been well controlled for two to three months in adults and for six months in children. The step-down process should be individualised for each patient. Preventive therapy should not be stopped completely.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
如何在控制良好的哮喘患者中减少哮喘预防药物的治疗-越多并不总是越好。
预防哮喘吸入器的大多数益处是在低剂量时看到的。然而,许多澳大利亚患者吸入的皮质类固醇剂量高于控制哮喘所需的剂量。开出不必要的高剂量预防剂会增加患者产生不良反应的风险。它们也可能增加病人的自付费用。哮喘指南建议在成人哮喘控制好2 - 3个月,儿童哮喘控制好6个月后,考虑逐步减少预防剂治疗。降压过程应针对每位患者个体化。预防治疗不应完全停止。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Australian Prescriber
Australian Prescriber MEDICINE, GENERAL & INTERNAL-PHARMACOLOGY & PHARMACY
CiteScore
3.80
自引率
7.40%
发文量
71
审稿时长
>12 weeks
期刊介绍: Australian Prescriber is Australia''s free, national, independent journal of drugs and therapeutics. It is published every two months online. Our purpose is to help health professionals make informed choices when prescribing, including whether to prescribe a drug or not. To do this we provide independent, reliable and accessible information. As well as publishing short didactic reviews, we facilitate debate about complex, controversial or uncertain therapeutic areas. We are part of NPS MedicineWise, an independent, non-profit organisation providing medicines information and resources for health professionals, and stakeholders involved in the quality use of medicines. NPS MedicineWise is funded by the Australian Government Department of Health.
期刊最新文献
Achieving safe medication management during transitions of care from hospital: time for a stewardship approach. Difelikefalin for pruritus associated with chronic kidney disease. Management of occupational exposure to blood and body fluids in primary care. Mineralocorticoid receptor antagonists in adults with resistant hypertension and obstructive sleep apnoea. Pharmacological management of polycystic ovary syndrome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1